September 11, 2023
Life Sciences | Tea Leaves
  • CVS Health said on Wednesday that it has launched a new company called Cordavis that will work directly with manufacturers to commercialize and co-produce biosimilar medicines for the U.S. market. CVS will initially work with the manufacturer Sandoz to produce a low-cost version of the blockbuster arthritis drug Humira. Humira — with a list price that tops $6,000 — lost its patent protection in July, opening the door to multiple biosimilar competitors. CVS said Wednesday that the Cordavis version, due to be released in the first quarter of 2024, will have a list price that’s more than 80 percent below Humira’s current price. (Articles here and here)